ASX:ACRAcrux Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acrux Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.14 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.14Now: A$0.14▼A$0.1450-Day RangeA$0.14MA: A$0.13▼A$0.1452-Week RangeA$0.11Now: A$0.14▼A$0.25Volume4,000 shsAverage Volume188,859 shsMarket Capitalization$22.74 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Acrux Limited, together with its subsidiaries, develops and commercializes specialty and generic topical pharmaceuticals in Australia, Switzerland, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was founded in 1998 and is based in West Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Acrux. Previous Next 2.6 Community Rank Outperform VotesAcrux has received 94 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcrux has received 85 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcrux has received 52.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acrux and other stocks. Vote “Outperform” if you believe ACR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcrux does not currently pay a dividend.Dividend GrowthAcrux does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrux insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acrux are expected to grow in the coming year, from A($0.04) to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrux is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrux is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrux has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:ACR Previous Symbol CUSIPN/A CIKN/A Webwww.acrux.com.au Phone+61-3-83790100Debt Debt-to-Equity Ratio15.02 Current Ratio6.93 Quick Ratio6.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.39 million Price / Sales6.71 Cash FlowA$0.09 per share Price / Cash Flow1.57 Book ValueA$0.09 per share Price / Book1.44Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares168,474,000Market Cap$22.74 million Next Earnings DateN/A OptionableNot Optionable Receive ACR News and Ratings via Email Sign-up to receive the latest news and ratings for ACR and its competitors with MarketBeat's FREE daily newsletter. Acrux (ASX:ACR) Frequently Asked Questions How has Acrux's stock been impacted by COVID-19 (Coronavirus)? Acrux's stock was trading at A$0.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACR stock has increased by 3.8% and is now trading at A$0.14. View which stocks have been most impacted by Coronavirus. How were Acrux's earnings last quarter? Acrux Limited (ASX:ACR) announced its quarterly earnings results on Thursday, February, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. View Acrux's earnings history. Has Acrux been receiving favorable news coverage? News headlines about ACR stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acrux earned a news impact score of -1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Acrux. Who are some of Acrux's key competitors? Some companies that are related to Acrux include Acasti Pharma (ACST), Helix Biopharma (HBP), Cocrystal Pharma (COCP), Ampio Pharmaceuticals (AMPE), Novoheart (NVH), Biopharmx (BPMX), Omega Diagnostics Group (ORPH), Orthocell (OCC), Cynata Therapeutics (CYP), Cohbar (CWBR), Pediapharm (PDP), Biotron (BIT), Cohbar (CWBR), Promis Neurosciences (PMN) and Sirona Biochem (SBM). View all competitors. What other stocks do shareholders of Acrux own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acrux investors own include Australia and New Zealand Banking Group (ANZ), Lynas (LYC), Altium (ALU), Atlas Iron (AGO), Hugo Boss (BOSS), BHP Group (BHP), Beacon Roofing Supply (BECN), Billabong (BBG), Abraxas Petroleum (AXAS) and Ausdrill (ASL). Who are Acrux's key executives? Acrux's management team includes the following people: Mr. Michael Kotsanis B.Sc., BSc, GradDipBus, MBus, CEO, MD & Exec. Director (Age 53)Mr. Tim Bateman, CFO & Company Sec.Ms. Felicia Colagrande BSc (Hons), MBA, Product Devel. & Technical Affairs DirectorMr. Charles O'Sullivan B. Pharm, Grad. Dip. Epi. & Biostats, Portfolio Director What is Acrux's stock symbol? Acrux trades on the ASX under the ticker symbol "ACR." What is Acrux's stock price today? One share of ACR stock can currently be purchased for approximately A$0.14. How big of a company is Acrux? Acrux has a market capitalization of $22.74 million and generates $3.39 million in revenue each year. What is Acrux's official website? The official website for Acrux is www.acrux.com.au. How can I contact Acrux? Acrux's mailing address is 103-113 Stanley St, MELBOURNE, VIC 3003, Australia. The company can be reached via phone at +61-3-83790100. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
